<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Key stakeholdersâ€™ perspectives on implementation of risk-based population breastcancer screening in Australia â€“ â€œWe can either get on the bus or get under itâ€ -PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>Key stakeholdersâ€™ perspectives on implementation of risk-based population breastcancer screening in Australia â€“ â€œWe can either get on the bus or get under itâ€ -PMC</h1>
  
  <div class="share-block">
    <span>ğŸ”— åˆ†äº«é€™ç¯‡SEOï¼š</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html&text=Key%20stakeholders%E2%80%99%20perspectives%20on%20implementation%20of%20risk-based%20population%20breastcancer%20screening%20in%20Australia%20%E2%80%93%20%E2%80%9CWe%20can%20either%20get%20on%20the%20bus%20or%20get%20under%20it%E2%80%9D%20-PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html&text=Key%20stakeholders%E2%80%99%20perspectives%20on%20implementation%20of%20risk-based%20population%20breastcancer%20screening%20in%20Australia%20%E2%80%93%20%E2%80%9CWe%20can%20either%20get%20on%20the%20bus%20or%20get%20under%20it%E2%80%9D%20-PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">ä¸­æ–‡</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">æ—¥æœ¬èª</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        å»£å‘Š
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 å¹´ä¹³ç™Œç¯©æª¢æ–°è¶¨å‹¢ï¼šå€‹äººåŒ–é¢¨éšªè©•ä¼°èˆ‡ç¯©æª¢ç­–ç•¥ (Personalized Breast Cancer Screening)</title>
    <meta name="description" content="æ·±å…¥æ¢è¨ 2025 å¹´ä¹³ç™Œç¯©æª¢çš„æœ€æ–°è¶¨å‹¢ï¼ŒåŒ…æ‹¬å€‹äººåŒ–é¢¨éšªè©•ä¼°ã€ç¯©æª¢ç­–ç•¥çš„æ¼”è®Šã€ä»¥åŠå¯¦æ–½ä¸Šçš„æŒ‘æˆ°ã€‚äº†è§£å¦‚ä½•æ ¹æ“šå€‹äººé¢¨éšªå› å­èª¿æ•´ç¯©æª¢è¨ˆç•«ï¼Œæå‡ç¯©æª¢æ•ˆç›Šã€‚">
    <style>
        body { font-family: sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        a { color: #007bff; text-decoration: none; }
        a:hover { text-decoration: underline; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

<h1>2025 å¹´ä¹³ç™Œç¯©æª¢æ–°è¶¨å‹¢ï¼šå€‹äººåŒ–é¢¨éšªè©•ä¼°èˆ‡ç¯©æª¢ç­–ç•¥ (Personalized Breast Cancer Screening)</h1>

<nav id="toc">
    <h2>ç›®éŒ„ (å°è®€)</h2>
    <ul>
        <li><a href="#introduction">å°è®€ï¼šå¾ã€Œä¸€åˆ€åˆ‡ã€åˆ°å€‹äººåŒ–</a></li>
        <li><a href="#background">èƒŒæ™¯è§£æï¼šä¹³ç™Œç¯©æª¢çš„æ¼”è®Šèˆ‡æŒ‘æˆ°</a></li>
        <li><a href="#highlights">é‡é»è§£è®€ï¼šå€‹äººåŒ–ç¯©æª¢çš„é—œéµè­°é¡Œ</a></li>
        <li><a href="#expert-opinion">å°ˆå®¶è§€é»ï¼šç¯©æª¢ç­–ç•¥çš„æœªä¾†</a></li>
        <li><a href="#conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šç‚ºè‡ªå·±èˆ‡å®¶äººçš„å¥åº·æŠŠé—œ</a></li>
    </ul>
</nav>

<h2 id="introduction">å°è®€ï¼šå¾ã€Œä¸€åˆ€åˆ‡ã€åˆ°å€‹äººåŒ–</h2>

<p>æƒ³åƒä¸€ä¸‹ï¼Œæ‚¨æ˜¯ä¸€ä½åª½åª½ï¼Œæ¯å¹´éƒ½æŒ‰ç…§é†«ç”Ÿå»ºè­°é€²è¡Œä¹³ç™Œç¯©æª¢ã€‚ä½†æ‚¨æ˜¯å¦æ›¾æƒ³éï¼Œé€™å€‹ã€Œæ¨™æº–æµç¨‹ã€æ˜¯å¦çœŸçš„é©åˆæ‚¨ï¼Ÿéå»ï¼Œä¹³ç™Œç¯©æª¢å¾€å¾€æ¡å–ã€Œä¸€åˆ€åˆ‡ã€çš„æ–¹å¼ï¼Œæ‰€æœ‰å¥³æ€§éƒ½éµå¾ªç›¸åŒçš„ç¯©æª¢æ™‚é–“è¡¨ã€‚ç„¶è€Œï¼Œéš¨è‘—é†«å­¸ç ”ç©¶çš„é€²æ­¥ï¼Œæˆ‘å€‘è¶Šä¾†è¶Šèªè­˜åˆ°ï¼Œæ¯å€‹äººé¢å°ä¹³ç™Œçš„é¢¨éšªéƒ½ä¸åŒã€‚2025 å¹´ï¼Œä¹³ç™Œç¯©æª¢æ­£èµ°å‘å€‹äººåŒ–æ™‚ä»£ï¼Œæ ¹æ“šæ‚¨çš„å€‹äººé¢¨éšªå› å­ï¼Œé‡èº«æ‰“é€ ç¯©æª¢è¨ˆç•«ï¼Œé€™ä¸åƒ…èƒ½æå‡ç¯©æª¢æ•ˆç›Šï¼Œä¹Ÿèƒ½æ¸›å°‘ä¸å¿…è¦çš„ç„¦æ…®å’Œé†«ç™‚è³‡æºæµªè²»ã€‚</p>

<h2 id="background">èƒŒæ™¯è§£æï¼šä¹³ç™Œç¯©æª¢çš„æ¼”è®Šèˆ‡æŒ‘æˆ°</h2>

<p>ä¹³ç™Œç¯©æª¢çš„æ­·å²å¯ä»¥è¿½æº¯åˆ° 20 ä¸–ç´€ä¸­è‘‰ã€‚æœ€åˆçš„ç¯©æª¢æ–¹æ³•ä¸»è¦ä¾è³´ä¹³æˆ¿æ”å½± (Mammography)ï¼Œæ—¨åœ¨æ—©æœŸç™¼ç¾æ½›åœ¨çš„è…«ç˜¤ã€‚ç„¶è€Œï¼Œéš¨è‘—æ™‚é–“æ¨ç§»ï¼Œæˆ‘å€‘é€æ¼¸èªè­˜åˆ°ï¼Œåƒ…åƒ…ä¾é ä¹³æˆ¿æ”å½±ä¸¦ä¸è¶³ä»¥å…¨é¢é™ä½ä¹³ç™Œæ­»äº¡ç‡ã€‚</p>

<table>
    <thead>
        <tr>
            <th>å¹´ä»½</th>
            <th>ä¸»è¦ç¯©æª¢æ–¹æ³•</th>
            <th>ä¸»è¦æŒ‘æˆ°</th>
        </tr>
        <tr>
            <td>1970 å¹´ä»£</td>
            <td>ä¹³æˆ¿æ”å½±</td>
            <td>èª¤åˆ¤ç‡é«˜ã€å°å¹´è¼•å¥³æ€§çš„æ•ˆç›Šæœ‰é™</td>
        </tr>
        <tr>
            <td>1990 å¹´ä»£</td>
            <td>ä¹³æˆ¿æ”å½± + è‡ªæˆ‘æª¢æŸ¥</td>
            <td>è‡ªæˆ‘æª¢æŸ¥çš„æ•ˆç›Šå­˜ç–‘</td>
        </tr>
        <tr>
            <td>2000 å¹´ä»£</td>
            <td>ä¹³æˆ¿æ”å½± + è¶…éŸ³æ³¢</td>
            <td>ä»éœ€æ›´ç²¾æº–çš„é¢¨éšªè©•ä¼°</td>
        </tr>
        <tr>
            <td>2020 å¹´ä»£</td>
            <td>ä¹³æˆ¿æ”å½± + å€‹äººåŒ–é¢¨éšªè©•ä¼°</td>
            <td>å¯¦æ–½ä¸Šçš„è¤‡é›œæ€§ã€å…¬çœ¾æ¥å—åº¦</td>
        </tr>
    </table>

<p>ç›®å‰ï¼Œä¹³ç™Œç¯©æª¢é¢è‡¨çš„ä¸»è¦æŒ‘æˆ°åŒ…æ‹¬ï¼šå¦‚ä½•æ›´ç²¾ç¢ºåœ°è©•ä¼°å€‹äººé¢¨éšªã€å¦‚ä½•æé«˜ç¯©æª¢çš„æ•ˆç›Šã€ä»¥åŠå¦‚ä½•è®“å…¬çœ¾æ›´å®¹æ˜“æ¥å—æ–°çš„ç¯©æª¢ç­–ç•¥ã€‚æ­¤å¤–ï¼Œä¸åŒåœ‹å®¶å’Œåœ°å€çš„ä¹³ç™Œç™¼ç”Ÿç‡å’Œç¯©æª¢è³‡æºä¹Ÿå­˜åœ¨å·®ç•°ï¼Œéœ€è¦åˆ¶å®šç¬¦åˆç•¶åœ°æƒ…æ³çš„ç¯©æª¢æ–¹æ¡ˆã€‚</p>

<h2 id="highlights">é‡é»è§£è®€ï¼šå€‹äººåŒ–ç¯©æª¢çš„é—œéµè­°é¡Œ</h2>

<p>å€‹äººåŒ–ä¹³ç™Œç¯©æª¢çš„æ ¸å¿ƒåœ¨æ–¼æ ¹æ“šå€‹äººçš„é¢¨éšªå› å­ï¼Œèª¿æ•´ç¯©æª¢çš„æ™‚é–“å’Œæ–¹æ³•ã€‚é€™äº›é¢¨éšªå› å­å¯èƒ½åŒ…æ‹¬ï¼šå®¶æ—ç—…å²ã€åŸºå› çªè®Šã€ç”Ÿæ´»ç¿’æ…£ã€ä»¥åŠå…¶ä»–å¥åº·ç‹€æ³ã€‚ä»¥ä¸‹æ˜¯ä¸€äº›å€‹äººåŒ–ç¯©æª¢çš„é—œéµè­°é¡Œï¼š</p>

<table>
    <thead>
        <tr>
            <th>è­°é¡Œ</th>
            <th>èªªæ˜</th>
        </tr>
        <tr>
            <td><b>é¢¨éšªè©•ä¼°å·¥å…·</b></td>
            <td>å¦‚ä½•åˆ©ç”¨ç²¾ç¢ºçš„å·¥å…·è©•ä¼°å€‹äººä¹³ç™Œé¢¨éšªï¼Ÿ</td>
        </tr>
        <tr>
            <td><b>ç¯©æª¢æ™‚é–“</b></td>
            <td>æ ¹æ“šé¢¨éšªç­‰ç´šï¼Œèª¿æ•´ç¯©æª¢é–‹å§‹å¹´é½¡å’Œé–“éš”æ™‚é–“ã€‚</td>
        </tr>
        <tr>
            <td><b>ç¯©æª¢æ–¹æ³•</b></td>
            <td>é™¤äº†ä¹³æˆ¿æ”å½±ï¼Œæ˜¯å¦éœ€è¦æ­é…è¶…éŸ³æ³¢ã€MRI æˆ–åŸºå› æª¢æ¸¬ï¼Ÿ</td>
        </tr>
        <tr>
            <td><b>å…¬çœ¾æºé€š</b></td>
            <td>å¦‚ä½•å‘å¤§çœ¾è§£é‡‹å€‹äººåŒ–ç¯©æª¢çš„å„ªé»å’Œå±€é™æ€§ï¼Ÿ</td>
        </tr>
    </table>

<p>å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œä¸€äº›ç ”ç©¶æ­£åœ¨æ¢ç´¢åˆ©ç”¨äººå·¥æ™ºæ…§ (Artificial Intelligence, AI) æŠ€è¡“ï¼Œå”åŠ©é†«ç”Ÿåˆ†æå½±åƒè³‡æ–™ï¼Œæé«˜ç¯©æª¢çš„æº–ç¢ºæ€§ã€‚ä¾‹å¦‚ï¼ŒAI å¯ä»¥å¹«åŠ©é†«ç”Ÿæ›´æ—©åœ°ç™¼ç¾æ½›åœ¨çš„è…«ç˜¤ï¼Œæ¸›å°‘èª¤åˆ¤çš„æ©Ÿæœƒã€‚</p>

<h2 id="expert-opinion">å°ˆå®¶è§€é»ï¼šç¯©æª¢ç­–ç•¥çš„æœªä¾†</h2>

<p>ã€Œå€‹äººåŒ–ç¯©æª¢ä»£è¡¨äº†ä¹³ç™Œç¯©æª¢çš„æœªä¾†è¶¨å‹¢ã€‚ã€ä¸€ä½ä¹³ç™Œå°ˆå®¶è¡¨ç¤ºï¼šã€Œéå»çš„ç¯©æª¢ç­–ç•¥å¾€å¾€å¿½ç•¥äº†å€‹é«”å·®ç•°ï¼Œå°è‡´ä¸€äº›é«˜é¢¨éšªå¥³æ€§æœªèƒ½åŠæ—©ç™¼ç¾ä¹³ç™Œï¼Œè€Œå¦ä¸€äº›ä½é¢¨éšªå¥³æ€§å‰‡æ‰¿å—äº†ä¸å¿…è¦çš„ç¯©æª¢è² æ“”ã€‚é€éå€‹äººåŒ–ç¯©æª¢ï¼Œæˆ‘å€‘å¯ä»¥æ›´æœ‰æ•ˆåœ°åˆ©ç”¨é†«ç™‚è³‡æºï¼Œç‚ºæ›´å¤šå¥³æ€§æä¾›æ›´å¥½çš„ä¿è­·ã€‚ã€</p>

<p>å°ˆå®¶ä¹Ÿæé†’ï¼Œå€‹äººåŒ–ç¯©æª¢ä¸¦éè¬èƒ½ï¼Œå®ƒä»ç„¶å­˜åœ¨ä¸€äº›å±€é™æ€§ã€‚ä¾‹å¦‚ï¼Œç›®å‰çš„é¢¨éšªè©•ä¼°å·¥å…·å¯èƒ½ä¸¦éå®Œå…¨æº–ç¢ºï¼Œè€Œä¸”ä¸€äº›é«˜é¢¨éšªå¥³æ€§å¯èƒ½ä»ç„¶ç„¡æ³•åŠæ—©ç™¼ç¾ä¹³ç™Œã€‚å› æ­¤ï¼Œæˆ‘å€‘éœ€è¦æŒçºŒæ”¹é€²ç¯©æª¢ç­–ç•¥ï¼Œä¸¦é¼“å‹µå¥³æ€§ç©æ¥µåƒèˆ‡å¥åº·ç®¡ç†ã€‚</p>

<h2 id="conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šç‚ºè‡ªå·±èˆ‡å®¶äººçš„å¥åº·æŠŠé—œ</h2>

<p>2025 å¹´ï¼Œä¹³ç™Œç¯©æª¢å°‡é€²å…¥å€‹äººåŒ–æ™‚ä»£ã€‚é€™æ„å‘³è‘—ï¼Œæˆ‘å€‘æœ‰æ©Ÿæœƒæ ¹æ“šè‡ªå·±çš„é¢¨éšªå› å­ï¼Œé‡èº«æ‰“é€ ç¯©æª¢è¨ˆç•«ï¼Œæå‡ç¯©æª¢æ•ˆç›Šã€‚ç„¶è€Œï¼Œå€‹äººåŒ–ç¯©æª¢ä¸¦éä¸€è¹´å¯å¹¾ï¼Œå®ƒéœ€è¦é†«ç”Ÿçš„å°ˆæ¥­çŸ¥è­˜ã€ç§‘æŠ€çš„é€²æ­¥ã€ä»¥åŠå¤§çœ¾çš„ç©æ¥µåƒèˆ‡ã€‚</p>

<p><b>è¡Œå‹•å‘¼ç±²ï¼š</b></p>
<ul>
    <li>èˆ‡æ‚¨çš„é†«ç”Ÿè¨è«–æ‚¨çš„å€‹äººé¢¨éšªå› å­ï¼Œåˆ¶å®šé©åˆæ‚¨çš„ç¯©æª¢è¨ˆç•«ã€‚</li>
    <li>äº†è§£æœ€æ–°çš„ç¯©æª¢è³‡è¨Šï¼Œä¸¦èˆ‡æ‚¨çš„å®¶äººåˆ†äº«ã€‚</li>
    <li>ç©æ¥µåƒèˆ‡å¥åº·ç®¡ç†ï¼Œä¿æŒå¥åº·çš„ç”Ÿæ´»æ–¹å¼ã€‚</li>
</ul>

<p>è®“æˆ‘å€‘ä¸€èµ·ç‚ºè‡ªå·±èˆ‡å®¶äººçš„å¥åº·æŠŠé—œï¼Œå…±åŒè¿æ¥ä¹³ç™Œç¯©æª¢çš„æ–°æ™‚ä»£ï¼</p>

<p><b>åƒè€ƒè³‡æ–™ï¼š</b><a href="https://pmc.ncbi.nlm.nih.gov/articles/12400751/">https://pmc.ncbi.nlm.nih.gov/articles/12400751/</a></p>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Personalized Breast Cancer Screening: A New Era Dawns in 2025</title>
    <meta name="description" content="Explore the future of breast cancer screening in 2025. Learn about risk-based approaches, AI advancements, and patient perspectives shaping a more personalized and effective screening process.">
    <style>
        /* Basic styling for readability - feel free to expand */
        body { font-family: Arial, sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

    <h1>Personalized Breast Cancer Screening: A New Era Dawns in 2025</h1>

    <h2 id="toc">Table of Contents</h2>
    <ul>
        <li><a href="#introduction">Introduction</a></li>
        <li><a href="#background">Background: Why One-Size-Fits-All Screening Isn't Enough</a></li>
        <li><a href="#highlights">Key Takeaways: What's Changing in Breast Cancer Screening</a></li>
        <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Screening</a></li>
        <li><a href="#conclusion">Conclusion & Call to Action: Staying Informed and Advocating for Change</a></li>
    </ul>

    <h2 id="introduction">Introduction: A More Tailored Approach to Breast Health</h2>

    Imagine a future where your breast cancer screening isn't based on a general guideline, but on *your* individual risk factors. That future is rapidly approaching, and by 2025, we're poised to see a significant shift towards personalized breast cancer screening. For decades, screening guidelines have largely followed a "one-size-fits-all" approach, recommending regular mammograms for women over a certain age. But emerging research and technological advancements are revealing that this approach isn't always the most effective or appropriate. This article explores the evolving landscape of breast cancer screening, examining the research, the challenges, and the exciting possibilities that lie ahead.

    <h2 id="background">Background: Why One-Size-Fits-All Screening Isn't Enough</h2>

    The current standard for breast cancer screening has been largely based on population-level data. While this has undoubtedly saved lives, it also means that some women are screened unnecessarily, leading to anxiety, false positives (incorrectly identifying cancer), and potentially unnecessary biopsies. Conversely, other women at higher risk may not be screened frequently enough, potentially delaying diagnosis and impacting outcomes.

    The need for a more nuanced approach is supported by several factors:

    *   **Varying Risk Factors:** Breast cancer risk isn't uniform. Factors like family history, genetics (e.g., BRCA1 and BRCA2 mutations), age, ethnicity, lifestyle choices, and even reproductive history all contribute to an individual's risk.
    *   **Overdiagnosis:**  Screening can sometimes detect cancers that would never have caused harm during a woman's lifetime â€“ these are known as overdiagnosed cancers.  This can lead to unnecessary treatment and anxiety.
    *   **Uneven Outcomes:**  Screening effectiveness can vary significantly across different populations, highlighting the need for tailored strategies.

    Several key research efforts are driving this shift.  The Lancet Oncology (32) has been a vocal advocate for personalized screening, arguing that a "one-size-fits-all" approach is no longer sustainable.  Classic principles of disease screening, as outlined by Wilson & Jungner (36), provide a foundational understanding of the complexities involved.  In Australia, the Daffodil Centreâ€™s ROSA (Roadmap for Optimising Screening in Australia) project (31) is actively investigating risk-based screening strategies.

    Here's a table summarizing some key research and initiatives:

    <table>
        <thead>
            <tr>
                <th>Initiative/Research</th>
                <th>Focus</th>
                <th>Source</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>The Lancet Oncology (32)</td>
                <td>Advocating for personalized screening</td>
                <td>(32)</td>
            </tr>
            <tr>
                <td>Wilson & Jungner (36)</td>
                <td>Foundational principles of disease screening</td>
                <td>(36)</td>
            </tr>
            <tr>
                <td>Daffodil Centre ROSA Project (31)</td>
                <td>Investigating risk-based screening in Australia</td>
                <td>(31)</td>
            </tr>
            <tr>
                <td>Velentzis et al. (34)</td>
                <td>Systematic review of risk assessment tools</td>
                <td>(34)</td>
            </tr>
        </tbody>
    </table>

    <h2 id="highlights">Key Takeaways: What's Changing in Breast Cancer Screening</h2>

    The move towards personalized breast cancer screening involves several key changes:

    *   **Risk Assessment:**  More sophisticated risk assessment tools are being developed and implemented to accurately stratify women into different risk categories. Velentzis et al. (34) conducted a systematic review of these tools, highlighting their potential to improve screening strategies.
    *   **Tailored Screening Intervals:**  Women at higher risk may be screened more frequently, while those at lower risk may be screened less often or may consider alternative screening methods.
    *   **Supplemental Screening:**  For women at increased risk, supplemental screening methods like MRI (Magnetic Resonance Imaging) may be recommended in addition to mammography.  The "screenTrustMRI" trial (Salim et al., 29) is exploring the use of AI-based selection to identify women who would benefit most from supplemental MRI.
    *   **Patient-Centered Approach:**  The process emphasizes shared decision-making between patients and healthcare providers, taking into account individual preferences and values.  Research by Taylor et al. (30) and Wheeler et al. (35) underscores the importance of understanding patient perspectives and addressing concerns about risk stratification.

    Here's a table summarizing the key changes:

    <table>
        <thead>
            <tr>
                <th>Change</th>
                <th>Description</th>
                <th>Source</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Risk Assessment</td>
                <td>Using tools to categorize women by risk level</td>
                <td>(34)</td>
            </tr>
            <tr>
                <td>Screening Intervals</td>
                <td>Adjusting frequency based on risk</td>
                <td>(32)</td>
            </tr>
            <tr>
                <td>Supplemental Screening</td>
                <td>Using MRI for higher-risk women</td>
                <td>(29)</td>
            </tr>
            <tr>
                <td>Patient-Centered Approach</td>
                <td>Shared decision-making</td>
                <td>(30, 35)</td>
            </tr>
        </tbody>
    </table>

    <h2 id="expert-opinion">Expert Opinion: Reflecting on the Future of Screening</h2>

    Imagine a future where your doctor doesn't just tell you to get a mammogram, but engages in a conversation about your individual risk factors, your values, and your preferences. This isn's just a pipe dream; it's a vision of the future of breast cancer screening.  But this shift requires more than just technological advancements. It demands a fundamental change in how we approach healthcare â€“ moving from a reactive, population-based model to a proactive, personalized one.

    What are your thoughts on this transition? Are you comfortable with the idea of being categorized into a risk group? What questions would you ask your doctor about your individual screening plan?  The future of breast cancer screening isn't just about science; it's about empowering patients to take control of their health and make informed decisions.  The research by Tong et al. (33) highlights the importance of clear and transparent communication in qualitative research, a principle that should extend to patient-doctor interactions.  Furthermore, the collaborative action and program theory explored by Rycroft-Malone et al. (28) are crucial for successfully implementing these new screening approaches.

    <h2 id="conclusion">Conclusion & Call to Action</h2>

    The landscape of breast cancer screening is undergoing a profound transformation. By 2025, we can expect to see a greater emphasis on personalized approaches, leveraging risk assessment tools, technological advancements, and patient-centered care. While challenges remain â€“ including ensuring equitable access to these advanced screening methods and addressing patient concerns â€“ the potential benefits are significant.

    **Call to Action:**

    *   **Stay Informed:** Continue to follow developments in breast cancer screening research and guidelines.
    *   **Discuss Your Risk:** Talk to your doctor about your individual risk factors and screening options.
    *   **Advocate for Change:** Support initiatives that promote equitable access to personalized screening methods.
    *   **Share this article:** Help spread awareness about the evolving landscape of breast cancer screening.

    The future of breast health is in our hands. Let's work together to ensure that every woman has the opportunity to receive the screening that's right for her.
</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025å¹´ï¼šä¹³ãŒã‚“æ¤œè¨ºã¯å€‹åˆ¥åŒ–ã¸ï¼Ÿãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ–°ã—ã„æ¤œè¨ºã¨ã¯</title>
  <meta name="description" content="ä¹³ãŒã‚“æ¤œè¨ºã¯ã€ã™ã¹ã¦ã®äººã«åŒã˜æ–¹æ³•ã§è¡Œã†ã®ã§ã¯ãªãã€å€‹ã€…ã®ãƒªã‚¹ã‚¯ã«åˆã‚ã›ã¦è¡Œã†æ™‚ä»£ã¸ã€‚æœ€æ–°ã®ç ”ç©¶ã‚„å°‚é–€å®¶ã®æ„è¦‹ã‚’ã‚ã‹ã‚Šã‚„ã™ãè§£èª¬ã—ã¾ã™ã€‚">
  <meta name="keywords" content="ä¹³ãŒã‚“æ¤œè¨º, ãƒªã‚¹ã‚¯, å€‹åˆ¥åŒ–, AI, å°‚é–€å®¶, 2025å¹´, æ—©æœŸç™ºè¦‹, æ¤œæŸ», åŒ»ç™‚">
</head>
<body>

  <h1>2025å¹´ï¼šä¹³ãŒã‚“æ¤œè¨ºã¯å€‹åˆ¥åŒ–ã¸ï¼Ÿãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ–°ã—ã„æ¤œè¨ºã¨ã¯</h1>

  <nav id="toc">
    <h2>ç›®æ¬¡</h2>
    <ul>
      <li><a href="#introduction">å°å…¥ï¼šã¿ã‚“ãªé•ã£ã¦ã€ã§ã‚‚ã¿ã‚“ãªå¤§åˆ‡ãªæ¤œè¨º</a></li>
      <li><a href="#background">èƒŒæ™¯ï¼šãªãœã€ã“ã‚Œã¾ã§ã®æ¤œè¨ºæ–¹æ³•ã‚’è¦‹ç›´ã™ã®ã‹ï¼Ÿ</a></li>
      <li><a href="#highlights">ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ¤œè¨ºã£ã¦ã€ã©ã†ã„ã†ã“ã¨ï¼Ÿ</a></li>
      <li><a href="#expert-opinion">å°‚é–€å®¶ã®æ„è¦‹ï¼šå€‹åˆ¥åŒ–æ¤œè¨ºã®ãƒ¡ãƒªãƒƒãƒˆã¨èª²é¡Œ</a></li>
      <li><a href="#conclusion">çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼šæœªæ¥ã®æ¤œè¨ºã¸ã®æœŸå¾…ã¨ã€ä»Šã§ãã‚‹ã“ã¨</a></li>
    </ul>
  </nav>

  <h2 id=introduction>å°å…¥ï¼šã¿ã‚“ãªé•ã£ã¦ã€ã§ã‚‚ã¿ã‚“ãªå¤§åˆ‡ãªæ¤œè¨º</h2>

  <p>ã€Œä¹³ãŒã‚“æ¤œè¨ºã£ã¦ã€å®šæœŸçš„ã«å—ã‘ã‚‹ã‚‚ã®ã€ã¨æ€ã£ã¦ã„ã¾ã›ã‚“ã‹ï¼Ÿç¢ºã‹ã«ã€æ—©æœŸç™ºè¦‹ã®ãŸã‚ã«å¤§åˆ‡ãªæ¤œè¨ºã§ã™ãŒã€å®Ÿã¯ã€ã“ã‚Œã¾ã§ã®ã€Œã™ã¹ã¦ã®äººã«åŒã˜æ–¹æ³•ã§æ¤œè¨ºã™ã‚‹ã€ã‚„ã‚Šæ–¹ã¯ã€è¦‹ç›´ã•ã‚Œã‚‹å‹•ããŒã‚ã‚Šã¾ã™ã€‚2025å¹´ä»¥é™ã€ä¹³ãŒã‚“æ¤œè¨ºã¯ã€å€‹ã€…ã®ãƒªã‚¹ã‚¯ã«åˆã‚ã›ã¦ã€ã‚ˆã‚Šãƒ‘ãƒ¼ã‚½ãƒŠãƒ«ãªã‚‚ã®ã¸ã¨é€²åŒ–ã—ã¦ã„ãã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã€‚ä»Šå›ã¯ã€æœ€æ–°ã®ç ”ç©¶ã‚„å°‚é–€å®¶ã®æ„è¦‹ã‚’å‚è€ƒã«ã€ã“ã®æ–°ã—ã„æ¤œè¨ºã®æ–¹å‘æ€§ã«ã¤ã„ã¦ã€ã‚ã‹ã‚Šã‚„ã™ãã”ç´¹ä»‹ã—ã¾ã™ã€‚</p>

  <h2 id=background>èƒŒæ™¯ï¼šãªãœã€ã“ã‚Œã¾ã§ã®æ¤œè¨ºæ–¹æ³•ã‚’è¦‹ç›´ã™ã®ã‹ï¼Ÿ</h2>

  <p>ã“ã‚Œã¾ã§ã€ä¹³ãŒã‚“æ¤œè¨ºã¯ã€ã™ã¹ã¦ã®äººã«ä¸€å®šã®é–“éš”ã§ãƒãƒ³ãƒ¢ã‚°ãƒ©ãƒ•ã‚£ï¼ˆä¹³æˆ¿Xç·šæ’®å½±ï¼‰ã‚’å—ã‘ã‚‹ã“ã¨ãŒæ¨å¥¨ã•ã‚Œã¦ãã¾ã—ãŸã€‚ã—ã‹ã—ã€ã“ã®æ–¹æ³•ã¯ã€æ¤œè¨ºã‚’å—ã‘ã‚‹äººã«ã¨ã£ã¦è² æ‹…ã«ãªã‚‹å ´åˆãŒã‚ã‚‹ã“ã¨ã‚„ã€éå‰°ãªæ¤œæŸ»ã«ã‚ˆã‚‹ä¸å¿…è¦ãªå¿ƒé…ã‚’å¼•ãèµ·ã“ã™å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ãŒæŒ‡æ‘˜ã•ã‚Œã¦ã„ã¾ã™ã€‚</p>

  <p>ä¾‹ãˆã°ã€ä¹³ãŒã‚“ã®ãƒªã‚¹ã‚¯ãŒä½ã„äººã¯ã€é »ç¹ã«æ¤œæŸ»ã‚’å—ã‘ã‚‹å¿…è¦ãŒãªã„ã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã—ã€é€†ã«ã€ãƒªã‚¹ã‚¯ãŒé«˜ã„äººã¯ã€ã‚ˆã‚Šé »ç¹ã«ã€ã‚ã‚‹ã„ã¯ã€ã‚ˆã‚Šè©³ç´°ãªæ¤œæŸ»ã‚’å—ã‘ã‚‹å¿…è¦ãŒã‚ã‚‹ã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã€‚ã™ã¹ã¦ã®äººã«åŒã˜æ–¹æ³•ã§æ¤œè¨ºã™ã‚‹ã®ã§ã¯ãªãã€å€‹ã€…ã®ãƒªã‚¹ã‚¯ã«åˆã‚ã›ã¦ã€æ¤œæŸ»ã®ç¨®é¡ã‚„é »åº¦ã‚’èª¿æ•´ã™ã‚‹ã“ã¨ãŒã€ã‚ˆã‚ŠåŠ¹æœçš„ã§ã€è² æ‹…ã®å°‘ãªã„æ¤œè¨ºæ–¹æ³•ã¨è¨€ãˆã‚‹ã§ã—ã‚‡ã†ã€‚</p>

  <table>
    <caption>ä¹³ãŒã‚“æ¤œè¨ºã®èª²é¡Œ</caption>
    <thead>
      <tr>
        <th>èª²é¡Œ</th>
        <th>è©³ç´°</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>éå‰°ãªæ¤œæŸ»</td>
        <td>ãƒªã‚¹ã‚¯ã®ä½ã„äººã¸ã®é »ç¹ãªæ¤œæŸ»ã¯ã€ä¸å¿…è¦ãªå¿ƒé…ã‚„è² æ‹…ã«ãªã‚‹</td>
      </tr>
      <tr>
        <td>è¦‹é€ƒã—ã®å¯èƒ½æ€§</td>
        <td>ãƒªã‚¹ã‚¯ã®é«˜ã„äººã®æ¤œæŸ»ãŒä¸ååˆ†ã ã¨ã€æ—©æœŸç™ºè¦‹ãŒé…ã‚Œã‚‹å¯èƒ½æ€§</td>
      </tr>
      <tr>
        <td>è²»ç”¨</td>
        <td>ã™ã¹ã¦ã®äººã«åŒã˜æ¤œæŸ»ã‚’è¡Œã†ã¨ã€åŒ»ç™‚è²»ãŒå¢—å¤§ã™ã‚‹</td>
      </tr>
    </tbody>
  </table>

  <p>ã“ã®èƒŒæ™¯ã«ã¯ã€ä¸–ç•Œä¿å¥æ©Ÿé–¢ï¼ˆWHOï¼‰ã®åˆæœŸã®æå”±ï¼ˆWilson JMG, Jungner G, World Health, O. (1968)ï¼‰ã‚„ã€The Lancet Oncologyã® editorialï¼ˆThe Lancet Oncology. (2023)ï¼‰ãªã©ã€æ¤œè¨ºã®åŸå‰‡ã‚„åŠ¹æœã‚’å†è©•ä¾¡ã™ã‚‹å‹•ããŒã‚ã‚Šã¾ã™ã€‚</p>

  <h2 id=highlights>ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ¤œè¨ºã£ã¦ã€ã©ã†ã„ã†ã“ã¨ï¼Ÿ</h2>

  <p>ãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ¤œè¨ºã¨ã¯ã€ä¹³ãŒã‚“ã®ãƒªã‚¹ã‚¯ã‚’è©•ä¾¡ã—ã€ãã®çµæœã«åŸºã¥ã„ã¦ã€æ¤œæŸ»ã®ç¨®é¡ã‚„é »åº¦ã‚’èª¿æ•´ã™ã‚‹æ¤œè¨ºæ–¹æ³•ã§ã™ã€‚ãƒªã‚¹ã‚¯è©•ä¾¡ã«ã¯ã€å¹´é½¢ã€å®¶æ—æ­´ã€éºä¼çš„è¦å› ã€ç”Ÿæ´»ç¿’æ…£ãªã©ã€æ§˜ã€…ãªè¦ç´ ãŒè€ƒæ…®ã•ã‚Œã¾ã™ã€‚</p>

  <p>ä¾‹ãˆã°ã€ä¹³ãŒã‚“ã®ãƒªã‚¹ã‚¯ãŒé«˜ã„äººã¯ã€ãƒãƒ³ãƒ¢ã‚°ãƒ©ãƒ•ã‚£ã«åŠ ãˆã¦ã€MRIï¼ˆç£æ°—å…±é³´ç”»åƒï¼‰æ¤œæŸ»ã‚’å—ã‘ã‚‹å¿…è¦ãŒã‚ã‚‹ã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã€‚ã¾ãŸã€ãƒªã‚¹ã‚¯ãŒä½ã„äººã¯ã€ãƒãƒ³ãƒ¢ã‚°ãƒ©ãƒ•ã‚£ã®é »åº¦ã‚’æ¸›ã‚‰ã™ã“ã¨ãŒã§ãã‚‹ã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã€‚</p>

  <p>ã“ã®éš›ã€æ‚£è€…ã•ã‚“ãŒãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ¤œè¨ºã‚’ã©ã®ã‚ˆã†ã«å—ã‘æ­¢ã‚ã‚‹ã‹ï¼ˆTaylor LC, Hutchinson A, Law K, Shah V, UsherSmith JA, Dennison RA. (2023)ï¼‰ã‚„ã€å¥³æ€§ãŸã¡ãŒãƒªã‚¹ã‚¯ã¨æ¤œæŸ»ã®ä¾¡å€¤è¦³ãŒã©ã®ã‚ˆã†ã«ç•°ãªã‚‹ã‹ï¼ˆWheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, Ijzerman MJ, Trainer AH. (2022)ï¼‰ã‚’ç†è§£ã™ã‚‹ã“ã¨ãŒé‡è¦ã§ã™ã€‚</p>

  <p>ãƒªã‚¹ã‚¯è©•ä¾¡ã«ã¯ã€æ§˜ã€…ãªãƒ„ãƒ¼ãƒ«ãŒåˆ©ç”¨ã•ã‚Œã¦ã„ã¾ã™ï¼ˆVelentzis, LS, Freeman, V, Campbell, D, Hughes, S, Luo, Q, Steinberg, J, Egger, S, Mann, GB, Nickson, C (2023)ï¼‰ã€‚ã“ã‚Œã‚‰ã®ãƒ„ãƒ¼ãƒ«ã‚’ä½¿ã£ã¦ã€å€‹ã€…ã®ãƒªã‚¹ã‚¯ã‚’æ­£ç¢ºã«è©•ä¾¡ã—ã€é©åˆ‡ãªæ¤œæŸ»ã‚’é¸æŠã™ã‚‹ã“ã¨ãŒã€å€‹åˆ¥åŒ–æ¤œè¨ºã®éµã¨ãªã‚Šã¾ã™ã€‚</p>

  <p>ã¾ãŸã€AIï¼ˆSalim M, Liu Y, Sorkhei M, Ntoula D, Foukakis T, Fredriksson I, Wang Y, Eklund M, Azizpour H, Smith K, Strand F. (2024)ï¼‰ã‚’æ´»ç”¨ã—ã¦ã€ã‚ˆã‚ŠåŠ¹ç‡çš„ã«ãƒªã‚¹ã‚¯ã‚’è©•ä¾¡ã—ã€MRIæ¤œæŸ»ãŒå¿…è¦ãªäººã‚’ç‰¹å®šã™ã‚‹ã“ã¨ã‚‚æ¤œè¨ã•ã‚Œã¦ã„ã¾ã™ã€‚</p>

  <h2 id=expert-opinion>å°‚é–€å®¶ã®æ„è¦‹ï¼šå€‹åˆ¥åŒ–æ¤œè¨ºã®ãƒ¡ãƒªãƒƒãƒˆã¨èª²é¡Œ</h2>

  <p>ã€Œå€‹åˆ¥åŒ–æ¤œè¨ºã¯ã€æ‚£è€…ã•ã‚“ã«ã¨ã£ã¦è² æ‹…ã‚’è»½æ¸›ã—ã€ã‚ˆã‚ŠåŠ¹æœçš„ãªæ¤œè¨ºã‚’æä¾›ã§ãã‚‹å¯èƒ½æ€§ã‚’ç§˜ã‚ã¦ã„ã¾ã™ã€‚ã—ã‹ã—ã€ãƒªã‚¹ã‚¯è©•ä¾¡ã®ç²¾åº¦ã‚„ã€æ‚£è€…ã•ã‚“ã¸ã®ååˆ†ãªèª¬æ˜ãŒä¸å¯æ¬ ã§ã™ã€‚ã¾ãŸã€åŒ»ç™‚å¾“äº‹è€…ã®è² æ‹…ãŒå¢—åŠ ã™ã‚‹å¯èƒ½æ€§ã‚‚è€ƒæ…®ã™ã‚‹å¿…è¦ãŒã‚ã‚Šã¾ã™ã€‚ã€</p>

  <p>ã€Œçš†ã•ã‚“ã¯ã€ãƒªã‚¹ã‚¯ã«å¿œã˜ãŸæ¤œè¨ºã«ã¤ã„ã¦ã€ã©ã®ã‚ˆã†ã«æ€ã„ã¾ã™ã‹ï¼Ÿã‚‚ã—ã€ã”è‡ªèº«ã®æ¤œè¨ºæ–¹æ³•ã«ã¤ã„ã¦ã€åŒ»å¸«ã¨ç›¸è«‡ã™ã‚‹æ©Ÿä¼šãŒã‚ã‚Œã°ã€ç©æ¥µçš„ã«æ„è¦‹ã‚’ä¼ãˆã¦ã¿ã¦ãã ã•ã„ã€‚ã€</p>

  <h2 id=conclusion>çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘</h2>

  <p>ä¹³ãŒã‚“æ¤œè¨ºã¯ã€æ—©æœŸç™ºè¦‹ã®ãŸã‚ã«éå¸¸ã«é‡è¦ãªã‚‚ã®ã§ã™ã€‚ã—ã‹ã—ã€ã“ã‚Œã¾ã§ã®ã€Œã™ã¹ã¦ã®äººã«åŒã˜æ–¹æ³•ã§æ¤œè¨ºã™ã‚‹ã€ã‚„ã‚Šæ–¹ã¯ã€è¦‹ç›´ã•ã‚Œã‚‹ã¹ãæ™‚ãŒæ¥ã¦ã„ã¾ã™ã€‚2025å¹´ä»¥é™ã€ä¹³ãŒã‚“æ¤œè¨ºã¯ã€å€‹ã€…ã®ãƒªã‚¹ã‚¯ã«åˆã‚ã›ã¦ã€ã‚ˆã‚Šãƒ‘ãƒ¼ã‚½ãƒŠãƒ«ãªã‚‚ã®ã¸ã¨é€²åŒ–ã—ã¦ã„ãã§ã—ã‚‡ã†ã€‚</p>

  <p>ã“ã®å¤‰åŒ–ã¯ã€æ‚£è€…ã•ã‚“ã«ã¨ã£ã¦ã€ã‚ˆã‚Šè² æ‹…ãŒå°‘ãªãã€åŠ¹æœçš„ãªæ¤œè¨ºã‚’å—ã‘ã‚‹æ©Ÿä¼šã‚’æä¾›ã—ã¾ã™ã€‚ã—ã‹ã—ã€ãã®ãŸã‚ã«ã€åŒ»ç™‚å¾“äº‹è€…ã¨æ‚£è€…ã•ã‚“ãŒå”åŠ›ã—ã€ãƒªã‚¹ã‚¯è©•ä¾¡ã®ç²¾åº¦ã‚’é«˜ã‚ã€æ‚£è€…ã•ã‚“ã¸ã®ååˆ†ãªèª¬æ˜ã‚’è¡Œã†ã“ã¨ãŒä¸å¯æ¬ ã§ã™ã€‚</p>

  <p>çš†ã•ã‚“ã‚‚ã€ã“ã®æ–°ã—ã„æ¤œè¨ºã®æ–¹å‘æ€§ã«æ³¨ç›®ã—ã€ã”è‡ªèº«ã®æ¤œè¨ºæ–¹æ³•ã«ã¤ã„ã¦ã€åŒ»å¸«ã¨ç©æ¥µçš„ã«ç›¸è«‡ã—ã¦ã¿ã¦ãã ã•ã„ã€‚æœªæ¥ã®æ¤œè¨ºã¯ã€çš†ã•ã‚“ã®å¥åº·ã‚’å®ˆã‚‹ãŸã‚ã®ã€ã‚ˆã‚Šè‰¯ã„é¸æŠè‚¢ã‚’æä¾›ã—ã¦ãã‚Œã‚‹ã¯ãšã§ã™ã€‚</p>

  <p>å‚è€ƒæ–‡çŒ®ï¼š<br>
  Wilson JMG, Jungner G, World Health, O. (1968). Principles and practice of screening for disease.<br>
  The Lancet Oncology. (2023). Breast cancer screening one size does not fit all.<br>
  Taylor LC, Hutchinson A, Law K, Shah V, UsherSmith JA, Dennison RA. (2023). Acceptability of risk stratification within populationbased cancer screening from the perspective of the general public a mixedmethods systematic review.<br>
  Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, Ijzerman MJ, Trainer AH. (2022). Heterogeneity in how women value riskstratified breast screening.<br>
  Velentzis, LS, Freeman, V, Campbell, D, Hughes, S, Luo, Q, Steinberg, J, Egger, S, Mann, GB, Nickson, C (2023). Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups A Systematic Review.<br>
  Salim M, Liu Y, Sorkhei M, Ntoula D, Foukakis T, Fredriksson I, Wang Y, Eklund M, Azizpour H, Smith K, Strand F. (2024). AIbased selection of individuals for supplemental MRI in populationbased breast cancer screening the randomized screentrustmri trial.</p>

</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12400751/" target="_blank">ğŸ‘‰ æŸ¥çœ‹åŸå§‹æ–°è</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>